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identiﬁcation of putative therapeutic target and vaccine candidate proteins from Kyoto Encyclopedia of
Genes and Genomes (KEGG) annotated metabolic pathways of Mycoplasma hyopneumoniae was performed
for drug design and vaccine production pipelines against M.hyopneumoniae. The employed comparative
genomic and metabolic pathway analysis with a predeﬁned computational systemic workﬂow extracted a
total of 41 annotated metabolic pathways from KEGG among which ﬁve were unique to M. hyopneumoniae. A
total of 234 proteins were identiﬁed to be involved in these metabolic pathways. Although 125 non homologous
and predicted essential proteins were found from the total that could serve as potential drug targets and vaccine
candidates, additional prioritizing parameters characterize 21 proteins as vaccine candidatewhile druggability of
each of the identiﬁed proteins evaluated by the DrugBank database prioritized 42 proteins suitable for drug
targets.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Mycoplasma hyopneumoniae, the causative agent of enzootic pneu-
monia, plays an important role in the swine industry worldwide causing
enormous economic loss affecting up to 80% of pigs around the world
[14]. The control of enzootic pneumonia by antimicrobial medication
and/or vaccinationunderﬁeld condition has been reportedly inadequate,
requiring additional optimized through herd management practices and
housing conditions [32,42]. This strongly indicates the need to search
new therapeutic targets and vaccine candidates that would offer better
protection, particularly optimizing both medication and vaccination in
preventing adhesion and colonization ofM. hyopneumoniae to the respi-
ratory tract and minimizing the high economic loss incurred.
The arrival of the post-genomic era has broughtwith it the possibility
of genome-wide application of a rational new drug target and vaccine
candidate selection methodology such as comparative and reductive
genomics using computational approaches with integrated data from
genomics, proteomics, and metabolomics [7,28].
In recent years the number of whole genome sequenced microbial
species has increased rapidly with already more than 2000 prokaryotic
whole genome sequences reported. Among those reported, several
Mycoplasma species have had their whole genome sequenced including, College of VeterinaryMedicine,
of Korea.
rights reserved.four strains of the swine pathogen M. hyopneumoniae [29,34,41].
Taking advantage of the whole genome sequence and the need for new
therapeutic target and vaccine candidate ofM. hyopneumoniae, we report
here the ﬁrst computational comparative genomic/proteomic analysis
aimed at the identiﬁcation of putative therapeutic targets and vaccine
candidate proteins ofM. hyopneumoniae.
2. Results
2.1. Identiﬁcation of metabolic pathways in M. hyopneumoniae
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a database
resource that integrates genomic, chemical, and systemic functional
information. In particular, gene catalogs in the completely sequenced
genomes are linked to higher-level systemic functions of the cell, the or-
ganism, and the ecosystem. As a result, KEGG iswidely used as a reference
knowledge base for integration and interpretation of large-scale datasets
generated by genome sequencing andother high-throughput experimen-
tal technologies. Currently, the KEGG database incorporates 41 different
pathways for the complete genome sequencedM. hyopneumoniae strain
232, 7448 and J [29,34,41] and 40 for strain 168. In addition, a total of
257 for M. hyopneumoniae swine host (Sus scrofa; TAX:9823) and 261
for human (Homo sapiens; TAX:9606) pathways is contained in the data-
base. The polycyclic aromatic hydrocarbon degradation (00624) pathway
was not present in strain 168. Strain 232, 7448 and J ofM. hyopneumoniae
had been reported to share about 663 (95%) of their genes which was
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However, this genome size was not inclusive of strain168. Hence, the ref-
erence M. hyopneumoniae 232 strain with a total of 691 gene products
was selected as representative for further analysis. Accordingly, identiﬁca-
tion of the unique and common pathways of the pathogenwith the refer-
ence strainM. hyopneumoniae 232was conductedmanuallywith the host
pathways according to our work ﬂow chart (Fig. 1). Five pathways were
identiﬁed as unique for the pathogen with the remaining 36 pathways
shared by both pathogen and host (Table 1). The comparison with the
human metabolic pathways revealed no difference and all the shared
pathways with the pathogen host were also shared by the human. Fur-
thermore, the number of proteins involved in each pathway was identi-
ﬁed (Table 1).
2.2. Non homologous and non homologous essential proteins
A total of 234 proteins were identiﬁed involved in both unique
and common pathways of the pathogen (Table S2). As a protein was
found to be involved in more than one pathway, among the 234 pro-
teins only two were found to be involved only in unique pathways of
the pathogens while the rest were shared either by both or involved
only in the common pathways. The comparisons of these protein
sequences against the swine host proteome using the special feature
of NCBI BLASTP revealed a total of 191 proteins with no hit against
the host proteome and these proteins were identiﬁed as non homol-
ogous proteins of the pathogen (Table S3). Both of the two proteins
from the unique pathways were found non homologous with no
hits to the host proteome. All the non homologous proteins identiﬁed
were further ﬁltered by homology searching against 9129 essentialFig. 1. Illustration of predeﬁned comparative and subtractive genomics systemic workﬂow
M. hyopneumoniae.genes from 22 bacteria in DEG (Table S1). This comparison performed
by using prokaryotic BLASTP from DEG detected 125 essential proteins
ofM. hyopneumoniae by similarities, which were also non-homologous
to swine host proteins (Table S4). The identiﬁed essential proteins had a
hit ranging from 1–20 of the 22 bacteria essential proteins in the DEG.
The highest hit of 107 was observed in M. pulmonis UAE CTIP essential
proteins. The total hits by each of the 22 bacteria in the DEG against
all 125 identiﬁed essential proteins above the threshold score are
presented in Fig. 2. One of the two proteins was involved only in the
unique pathways mapped to essential proteins of the DEG database.
However, all the non-homologous essential proteins represent an
attractive dataset that could be exploited for future drug design and
vaccine production againstM. hyopneumoniae.
2.3. Prioritization of target proteins
Although all the 125 identiﬁed non homologous proteins of the
pathogen represent potential targets for therapeutic and vaccine can-
didates, prioritization and more ﬁltration of the identiﬁed proteins
could help to minimize the time, labor and resources for developing
the therapeutic agent and optimize the success of getting the best
drug and/or vaccine against the pathogen. Hence, additional parame-
ters that determine the suitability of a drug and vaccine target were
used to characterize the identiﬁed target proteins. The characteriza-
tion of subcellular localization by CELLO server identiﬁed 21 mem-
brane proteins. From determined molecular weight in Swiss-Prot
database we identiﬁed only 4 proteins with molecular mass >110
while the TMHMM identiﬁed 18 transmemebrane proteins. We
found no single entry for experimental conﬁrmed 3D structure in. Steps involved in computational comparative genomics based target identiﬁcation in
Table 1
Unique and common metabolic pathways of M. hyopneumoniae with reference to its
swine host and human.
No. Unique pathways (KEGG) KEGG pathway
ID
Total
proteins
1 Streptomycin biosynthesis 00521 3
2 Polycyclic aromatic hydrocarbon degradation 00624 1
3 Methane metabolism 00680 8
4 Phosphotransferase system (PTS) 02060 12
5 Bacterial secretion system 03070 8
No. Common pathways (KEGG) KEGG pathway
ID
Total
proteins
1 Glycolysis/gluconeogenesis 00010 19
2 Citrate cycle (TCA cycle) 00020 5
3 Pentose phosphate pathway 00030 11
4 Fructose and mannose metabolism 00051 9
5 Galactose metabolism 00052 2
6 Ascorbate and aldarate metabolism 00053 9
7 Oxidative phosphorylation 00190 11
8 Purine metabolism 00230 21
9 Pyrimidine metabolism 00240 23
10 Glycine, serine and threonine metabolism 00260 4
11 Cysteine and methionine metabolism 00270 5
12 Valine, leucine and isoleucine degradation 00280 3
13 Taurine and hypotaurine metabolism 00430 2
14 Selenocompound metabolism 00450 2
15 Glutathione metabolism 00480 1
16 Starch and sucrose metabolism 00500 3
17 Amino sugar and nucleotide sugar metabolism 00520 7
18 Glycerolipid metabolism 00561 3
19 Inositol phosphate metabolism 00562 8
20 Glycerophospholipid metabolism 00564 6
21 Pyruvate metabolism 00620 10
22 Propanoate metabolism 00640 5
23 Riboﬂavin metabolism 00740 2
24 Nicotinate and nicotinamide metabolism 00760 5
25 Lipoic acid metabolism 00785 2
26 Aminoacyl-tRNA biosynthesis 00970 23
27 ABC transporters 02010 21
28 Ribosome 03010 47
29 RNA degradation 03018 4
30 RNA polymerase 03020 3
31 DNA replication 03030 12
32 Protein export 03060 10
33 Base excision repair 03410 5
34 Nucleotide excision repair 03420 6
35 Mismatch repair 03430 10
36 Homologous recombination 03440 12
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among the 125 non homologous essential proteins. All these results
are summarized and presented in Table S4. Although the identiﬁed 21
membrane proteins could directly be taken as potential vaccine candi-
dates, we have further characterized them by theMMPPP for identiﬁca-
tion of any predicted antigenic peptide epitopes. All the 21 proteins
were found to have antigenic peptide epitope with a cleavage probabil-
ity of 1 and a binding score ranging from 0.6125 to 0.8946. The results of
all the identiﬁed predicted antigenic peptide epitopes are summarized
in Table S5.
2.4. Druggability of therapeutic targets
The BLASTP search aligning the non homologous essential proteins to
the list of drug targeted proteins downloaded from DrugBank was used
to examine the druggability of each of the nonhomologous essential pro-
teins. The BLASTP alignment search identiﬁed 42M. hyopneumoniae pro-
teins highly similar to the binding partners of all the drug target proteins
(Table 2). Among these 22 were FDA-approved drugs or nutraceuticals
or approved under investigation or biotechs and the remaining 20
are small molecule compounds or biotechs under experimentation.
Additionally, the identiﬁed drug targeted proteins produced a list ofexperimental, approved drugs, nutraceuticals and biotechs that binds
to these. In Table 3 we summarized the identiﬁed target protein binding
partners of FDA-approved drug list of the 22 M. hyopneumoniae target
proteins.
2.5. Distributions of essential proteins/genes to metabolic pathways
The distribution and association of the essential gene/proteins
were compared in two stages; ﬁrst, next to the identiﬁcation of the
non homologous essential genes of M. hyopneumoniae and second,
after similarity search of the non homologous with the DrugBank
database, i.e. before and after the non homologous essential proteins/
genes were analyzed by homology search to DrugBank database of all
drug targets (Fig. 3). The distribution of the number of non homologous
essential proteins/genes after DrugBank search reduced by ~65% and
the pathways by ~32% which also led to the shift of the priority targets,
ribosome, pyrimidinemetabolism, purinemetabolism, ABC transporters
and aminoacyle-tRNA biosynthesis pathways according to concentra-
tions in descending order (Fig. 3A) to ribosome, aminoacyle-tRNA bio-
synthesis and purine (Fig. 3B). Although the non homologous essential
genes/proteins in ABC transporters had a high number of hits their
similarity score remains under threshold.
3. Discussion
Recently, the search for drug targets using computational
methods and integrated ‘omics’ data, such as genomics, proteomics,
and metabolomics, has received much attention and has been in-
creasing continuously, for instance, comparative and subtractive
genomics have been widely used for the prediction and identiﬁcation
of potential therapeutic targets and vaccine candidate proteins in
numerous pathogenic bacteria and also fungi [2,9,11,23,43]. These com-
putational methods coupled with the availability of four strains of
whole genome sequenced M. hyopneumoniae provide us the prospect
to perform the ﬁrst computational comparative and subtractive geno-
mic analysis aimed at the identiﬁcation of putative therapeutic targets
and vaccine candidate proteins of M. hyopneumoniae. In the current
study the comparisons of initial information of metabolic pathways
obtained from the KEGG database revealed the same type and number
of metabolic pathways among the four strains of M. hyopneumoniae
except for the polycyclic aromatic hydrocarbon degradation pathway
which was not present in M. hyopneumoniae strain 168. The conserva-
tion of all the metabolic pathways more speciﬁcally genes involved in
themetabolic pathways among the strains is amajor determining factor
in the attempt to identify species speciﬁc therapeutic drug target and
vaccine candidate proteins. Moreover, previous studies have also indi-
cated conservation among genomes is itself a predictive feature for
essentiality of genes in predicting drug targets [11]. Hence, our further
insight in genes involved in the pathway of polycyclic aromatic hydro-
carbon degradation revealed a single gene characterized as DNA meth-
ylase. The protein sequence of this gene product was found less by 24
amino acids in strain 168 suggesting the reason for the KEGG in not pre-
dict the pathway in this strain [29,34,41]. Our further insight into each
of themetabolic pathways revealed that all the proteins/genes involved
in the unique metabolic pathways of bacterial secretion system and
methane metabolism were shared with common pathways. This
shows that essentially the two pathways are not unique to the patho-
gen, although they were unique in the direct comparisons of the patho-
gen pathway list against the swine host.
The possibilities of selecting targets using computational approaches
with integrated ‘omics’ data rely on searching for those genes/proteins
that are absent in the host and/or non homologous to the host proteome
but present in the pathogen as designing a drug speciﬁc to such targets
will have effect only on the pathogen and not any other aspect of
the host biology [8]. In this aspect our results of the non homologous
proteins of M. hyopneumoniae through the NCBI BLASTP search against
Fig. 2. Frequency of hits ofM. hyopneumoniae proteins by the 22 bacteria in DEG. Distance from the center are the number of hits of the 125 proteins by essential proteins of the 22
bacteria in DEG.
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human pathogen Mycoplasma genitalium (M. genitalium) in which only
79 non homologous proteins were identiﬁed [7]. This prompted us to re-
peat the homology search against the human proteome, yet it had
resulted in a similar outcome with only a single additional homologous
protein to the human proteome but non homologous to the pathogen
host. However, the number and/or proportion of non homologous pro-
teins identiﬁed from unique pathways were lower inM. hyopneumoniae
thanM. genitalium.
The potential of the identiﬁednon homologous proteins to be a ther-
apeutic target of a given pathogen gene product is dependent on two
broad types of information. First, the role of the gene in the growth
and survival of the pathogen deﬁning the essentiality of genes/proteins
and second, the likelihood of being able to develop a compound that
modulates that target into a drug deﬁning the druggability of the target
proteins [1]. These parameters have been used in drug target prioritiza-
tion inMycobacterium ulcerans [8] Burkholderia pseudomallei [9] andM.
genitalium [8]. Although the search for drug targets among essential
genes is a useful approach and considered an important parameter for
the prioritization of targets, the inability of this methodology to predict
some of the successful drug targets (false negatives) and inclusions of
non drug targets (false positives) is a limitation of this practice [1,11].
There have been several attempts to deﬁne or predict essential genes
in infectious agents through systematic disruption of candidate genes
and transposon mutagenesis, for example, in Streptococcus pneumoniae
(S. pneumoniae), Mycobacterium tuberculosis (M. tuberculosis) and M.
genitalium [17,38,40]. However, for the vast majority of infectious or-
ganisms, high throughput experimental interrogation of essentiality is
currently not possible, and efforts to deﬁne essentiality have been
based on bioinformatic predictions [1,11,43]. Consistent with this, 7 of
8 computationally predicted essential genes via DEG-based homology
search were also experimentally validated as essential for Yersinia pseu-
dotuberculosis (Y. pseudotuberculosis) [12]. Here, we have attempted topredict the essentiality of nonhomologous proteins ofM. hyopneumoniae
following a similar fashion based on bioinformatic predictions through
homology searchwith the already identiﬁed essential gene/protein data-
base from 22 bacteria in DEG [45,46]. This approach ﬁltered and reduced
34.03% of the nonhomologous proteins ofM. hyopneumoniaeprotein tar-
gets. Although the reduction was twice higher proportionally compared
with a similar report onM. genitaliumwhich had reduced by 15.18%, the
number of essential non homologous proteins was still higher in this
study. However, this is not unexpected as a previous experiment in glob-
al transposon mutagenesis of M. genitalium and M. pulmonis reported
382 and 310 protein-coding essential genes, respectively [15,19]. This
was also evidenced by the number of total hits observed for the essential
genes of M. hyopneumoniae by M. genitalium next to M. pulmonis UAB
CTIP and Staphylococcus aureus(S. aureus) N315 (Fig. 2). Hence, the
difference could be attributed for the higher similarity or homologous
proteins identiﬁed in the human proteome by M. genitalium than M.
hyopneumoniae.
Advances in genome sequencing, bioinformatics and cheminformatics
coupled with experimental data have shown several additional factors
such as molecular mass (b110), subcellular localization, whether the
protein is transmembrane and availability of 3D structural information
that can aid in determining the suitability of therapeutic targets besides
identifying the proteins of the pathogen as non homologous and essential
protein [1,7,8]. Proteins with smaller molecular mass were found very
likely to be soluble and easier to purify [12]. The characterization and
prioritization of the proteins using their molecular mass resulted in
much of the identiﬁed non homologous essential proteins to be less
than 110 (96.73%, n = 126) suggesting higher possibility of experimen-
tal veriﬁcation of many of the identiﬁed proteins for drug targets (Table
S4). Furthermore, among the critical reasons mentioned for knowledge
of the localization of proteins within cellular compartments, the factor
that aids in determining the suitability of therapeutic targets, is under-
standing their function which yields important insight that can lead to
Table 2
Non-homologous essential proteins ofM. hyopneumoniae similar to binding partners of FDA approved drugs, experimental small molecule compounds, or nutraceutical compounds
as inferred from DrugBank database using BLASTP.
No. Gene name Protein ID Pathways involved name (ID) Protein existence Subcellular location TMHMMa
no.
3D Expb 3D Model MW (KDa)
1 fba Q602D6 Glycolysis/gluconeogenesis (00010) Predicted Cytoplasmic No No Yes 31
Pentose phosphate pathway (00030)
Fructose and mannose metabolism (00051)
Methane metabolism (00680)
2 ictD P0C0J2 Glycolysis/gluconeogenesis (00010) cInferred H Cytoplasmic No No Yes 34
Cysteine and methionine metabolism (00270)
Pyruvate metabolism (00620)
Propanoate metabolism (00640)
3 pdhA Q601D7 Glycolysis/gluconeogenesis (00010) Predicted Cytoplasmic No No Yes 42
Citrate cycle (TCA cycle) (00020)
Pyruvate metabolism (00620)
4 pgi Q600A8 Glycolysis/gluconeogenesis (00010) Inferred H Cytoplasmic No No Yes 46
Pentose phosphate pathway (000300
Starch and sucrose metabolism (00500)
Amino sugar and nucleotide sugar metabolism (00520)
5 pdhD Q5ZZX0 Glycolysis/gluconeogenesis (00010) Inferred H Cytoplasmic No No Yes 51
Citrate cycle (TCA cycle) (00020)
Glycine, serine and threonine metabolism (00260)
Valine, leucine and isoleucine degradation (00280)
Pyruvate metabolism (00620)
6 hpt Q601T4 Purine metabolism (00230) Predicted Cytoplasmic No No Yes 20
7 nrdE Q601P3 Purine metabolism (00230) Inferred H Membrane No No Yes 82
Pyrimidine metabolism (00240)
8 adk Q601J4 Purine metabolism (00230) Inferred H Cytoplasmic No No Yes 24
9 rpoA Q601I9 Purine metabolism (00230) Inferred H Cytoplasmic No No Yes 37
Pyrimidine metabolism (00240)
RNA polymerase (03020)
10 rpoB Q5ZZS1 Purine metabolism (00230) Inferred H Membrane No No Yes 138
Pyrimidine metabolism (00240)
RNA polymerase (03020)
11 cmk Q601X7 Pyrimidine metabolism (00240) Inferred H Cytoplasmic No No Yes 26
12 trxB Q601C1 Pyrimidine metabolism (00240) Inferred H Cytoplasmic No No Yes 34
Selenocompound metabolism (00450)
13 upp Q600B3 Pyrimidine metabolism (00240) Predicted Cytoplasmic No No Yes 23
14 mmsA Q601P8 Valine, leucine and isoleucine degradation (00280) Inferred H Cytoplasmic No No Yes 54
Inositol phosphate metabolism (00562)
Propanoate metabolism (00640)
15 pta Q600E9 Taurine and hypotaurine metabolism (00430) Predicted Cytoplasmic No No Yes 35
Pyruvate metabolism (00620)
Propanoate metabolism (00640)
Methane metabolism (00680)
16 metG Q600P5 Selenocompound metabolism (00450) Predicted Cytoplasmic No No Yes 62
Aminoacyl-tRNA biosynthesis (00970)
17 nagB Q5ZZW6 Amino sugar and nucleotide sugar metabolism (00520) Predicted Cytoplasmic No No Yes 29
18 gatB Q602C0 Aminoacyl-tRNA biosynthesis (00970) Inferred H Cytoplasmic No No Yes 54
19 tyrS Q601Y5 Aminoacyl-tRNA biosynthesis (00970) Inferred H Cytoplasmic No No Yes 48
20 pheS Q601U5 Aminoacyl-tRNA biosynthesis (00970) Predicted Cytoplasmic No No Yes 26
21 serS Q601S3 Aminoacyl-tRNA biosynthesis (00970) Predicted Cytoplasmic No No Yes 47
22 gltX Q601G1 Aminoacyl-tRNA biosynthesis (00970) Inferred H Cytoplasmic No No Yes 55
23 valS Q5ZZL4 Aminoacyl-tRNA biosynthesis (00970) Inferred H Cytoplasmic No No Yes 97
24 ptsI Q600I5 Phosphotransferase system (PTS) (02060) Inferred H Cytoplasmic No No Yes 64
25 rpsB Q601Z3 Ribosome (03010) Inferred H Cytoplasmic No No Yes 36
26 rpsG Q601W7 Ribosome (03010) Inferred H Cytoplasmic No No Yes 18
27 rpsL Q601W6 Ribosome (03010) Inferred H Cytoplasmic No No Yes 15
28 rplC Q601L5 Ribosome (03010) Inferred H Cytoplasmic No No Yes 25
29 rplD Q601L4 Ribosome (03010) Inferred H Cytoplasmic No No Yes 24
30 rpsS Q601L1 Ribosome (03010) Inferred H Cytoplasmic No No Yes 10
31 rpsC Q601K8 Ribosome (03010) Inferred H Cytoplasmic No No Yes 25
32 rpsH Q601K0 Ribosome (03010) Inferred H Cytoplasmic No No Yes 14
33 rpsE Q601J7 Ribosome (03010) Inferred H Cytoplasmic No No Yes 24
34 rpsM Q601J1 Ribosome (03010) Inferred H Cytoplasmic No No Yes 16
35 rplK Q600J6 Ribosome (03010) Inferred H Cytoplasmic No No Yes 16
36 rpsD Q5ZZW4 Ribosome (03010) Inferred H Cytoplasmic No No Yes 24
37 rpsI Q5ZZN6 Ribosome (03010) Inferred H Cytoplasmic No No Yes 15
38 lig Q601T8 DNA replication (03030) Inferred H Cytoplasmic No No Yes 79
Base excision repair (03410)
Nucleotide excision repair (03420)
Mismatch repair (03430)
39 ftsY Q602E2 Protein export (03060) Predicted Cytoplasmic No No Yes 37
Bacterial secretion system (03070)
40 secA Q601A7 Protein export (03060) Inferred H Cytoplasmic 0 No Yes 112
Bacterial secretion system (03070)
(continued on next page)
51D. Damte et al. / Genomics 102 (2013) 47–56
Table 2 (continued)
No. Gene name Protein ID Pathways involved name (ID) Protein existence Subcellular location TMHMMa
no.
3D Expb 3D Model MW (KDa)
41 recA Q602A9 Homologous recombination (03440) Inferred H Cytoplasmic No No Yes 36
42 ruvB Q600N3 Homologous recombination (03440) Inferred H Cytoplasmic No No Yes 36
a Number of transmembrane protein predicted by THMMH.
b Experimentally conﬁrmed 3D structure.
c Inferred homology.
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21 proteins from the non homologous essential proteins identiﬁed using
CELLO server were in line with the prediction of 18 transmembrane by
TMHMMwhich were among the 21 predicted earlier. These targets rep-
resent potential vaccine candidates for development of an effective vac-
cine against M. hyopneumoniae as many of the vaccines that protect by
eliciting antibody mediated immunity appear to be secreted toxins and/
or highly expressed, surface exposed molecules [10]. The new genomic
based approaches shown to be very powerful for the discovery of vaccine
candidates are labor intensive and time consuming in that the identiﬁca-
tion of the few protective antigens requires the screening of a large num-
ber of recombinant proteins in biological assays usually involving animal
models [16,23]. Hence, the current approach could be a response to the
highly desirable strategy that substantially reduces the number of pro-
teins to be tested.
Although M. hyopneumoniae is a highly studied swine respiratory
pathogen with the whole genome of 4 of its strains already sequenced,
there is no single experimentally veriﬁed protein within the PDB
database, indicating the gap in the available study of protein structure
and the skewedness of research areas in M. hyopneumoniae. However,
most of the essential non homologs have a 3D model in Modbase.
Structure libraries of drug target proteins play a key role in drug design,
enabling computational methods to score and rank the predicted
afﬁnity between drugs and targets. This process is known as virtual
screening and has reduced the costs of experimental high-throughput
assays. Virtual screening is knowledge-based and requires structural
information of the target and ligand (ligand-based screening) or of
the target alone (target-based screening) [19,35].
The second determinant for the potential of a non homologous
protein to be a therapeutic target, the druggability of the protein,
was determined with the homology search against the DrugBank
target proteins. This search besides its advantage of identiﬁcation of
the pathogen proteins that are highly similar to the binding partners
of all drug targets of DrugBank and reducing the testable proteins to
42, produced a list of different types of drugs in the DrugBank that
bind to proteins of the pathogen. However, the protein sequence
similarity search had limitations in that it does not assure the struc-
ture or biding pockets identicalness of the identiﬁed similar proteins.
Our attempt to further validate and characterize the proteins through
3D homology search had also failed for the absence of experimentally
conﬁrmed 3D structure in the databases of PDB as mentioned above
and also in the literature. Among the identiﬁed FDA drug lists none
matched to the known virulence factors such as P97 adhesion protein.
This could be due to the non essential nature of the virulence factors
that would exclude them from the list as essential proteins of the
pathogen.
Finally whenwe come to speciﬁc targets identiﬁed, from the unique
metabolic pathways, a single protein i.e. phosphoenolpyruvate-protein
phosphotransferase (ptsI) enzyme from phosphotransferase system
(PTS) pathway was identiﬁed as drug target againstM. hyopneumoniae.
This pathway is a major mechanism of carbohydrate metabolism and
critical for growth and survival of the bacteria. This was the only target
protein identiﬁed from the unique pathways of M. hyopneumoniae
not shared with common pathways and also previously reported in
M. genitalium [7]. Although there were several essential non homolo-
gous identiﬁed protein targets from unique pathways of the pathogen
observed to be involved in multiple pathways of the commonpathways, there were no drug targets identiﬁed shared by the unique
pathway (Fig. 3). However, there was good number of vaccine candi-
dates identiﬁed from essential non homologous proteins shared by
both unique and common pathways as several of them were predicted
to be membrane proteins (Table S4). Several of the targets were found
to be involved in multiple pathways and targeting these proteins may
lead to development of more potent drugs.
Both fructose-bisphosphate aldolase (fba) an enzyme that catalyzes
a reversible reaction required for both glycolysis and gluconeogenesis
and glucose-6-phosphate isomerase (pgi) an enzyme that catalyzes
the reversible isomerization of D-glucose 6-phosphate to D-fructose
6-phosphate in the glycolysis pathway which have been previously
reported as targets of antifungal and anti-protozoa drugs, respectively
[31,37] were found as drug targets for experimental small molecule
compounds in DrugBank in the current study. DNA ligase (lig), a key
enzyme that catalyzes the formation of phosphodiester bonds at single
stranded or double stranded breaks between adjacent 5′ phosphoryl
and 3′ hydroxyl groups of DNA, is an important enzyme for survival be-
cause of its involvement inmajor cellular processes like DNA replication/
repair and recombination [13]. However, this target albeit previous re-
ports as drug target of antibiotics specially in overcoming current drug
resistance issues did not achieve a threshold similarity with any of the
FDA approved drug targets from DrugBank. Besides the above three
enzymes involved in multiple pathways of M. hyopneumoniae with hits
for only experimental drug targets of the DrugBank with no previous
reports was phosphate acetyltransferase (pta).
L-lactate dehydrogenase (L-LDH) protein also called immunogenic
protein p36 was among the drug targets found to be involved in
multiple common pathways and highly similar to the binding partner
of one FDA-approved and four experimental drug targets from
DrugBank (Table 3). This protein has been previously conﬁrmed to pro-
duce strong immunogenic reaction, however antibodies raised against
M. hyopneumoniae do not inhibit its growth or metabolic activities as
conﬁrmed experimentally [21]. Hence, the potential as drug target
remains open for experimental validation. The other two drug target
proteins identiﬁed involved in multiple common pathways with hits
of FDA approved drug targets, are methylmalonate-semialdehyde
dehydrogenase (mmsA) and dihydrolipoyl dehydrogenase (pdhD) the
functions of which have been studied in Bacillus subtilis for the earlier
[39] andM. hyopneumoniae itself for the later [33] which have indicated
a critical role in the energy metabolism and transcriptions of an
organism symptomatic of the possibility of their potential role in the
development of a drug against M. hyopneumoniae. Furthermore, the
higher distribution of FDA approved drug targets in ribosome and
aminoacyl-tRNA biosynthesis common pathways of the pathogen
(Fig. 3) prompted us for more insight in these pathways. We observed
an increasing interest in the assembly of bacterial ribosomes as a
potential target for new antibiotics especially with the recently detailed
review. In this review the assembly of ribosomes which begins with
transcription of rRNA from multiple copies of rRNA operons had been
reported to disfavor resistance by the need to mutate multiple
copies unlike mutations in the singly encoded ribosomal proteins, and
for this reason antibiotics that target the rRNA had become attractive
[6].
Aminoacyl-tRNA biosynthesis, the second common pathway with
higher distributionof identiﬁed targets, hadbeen also previously reported
in M. genitalium for its multiple target enzymes whose inhibition could
Table 3
Non-homologous essential proteins of M. hyopneumoniae similar to binding partners of FDA approved drugs as inferred from DrugBank database using BLASTP and the list of FDA
approved drugs for the targets.
NO Protein ID Pathways involved name (ID) DrugBank ID Drug name list Drug group
1 P0C0J2 Glycolysis/gluconeogenesis (00010),
cysteine and methionine metabolism
(00270), pyruvate metabolism (00620),
propanoate metabolism (00640)
DB00157 NADH Approved, nutraceutical
2 Q601D7 Glycolysis/gluconeogenesis (00010), citrate
cycle (TCA cycle) (00020), pyruvate
metabolism (00620)
DB00157 NADH Approved, nutraceutical
3 Q5ZZX0 Glycolysis/gluconeogenesis (00010), citrate
cycle (TCA cycle) (00020), glycine, serine
and threonine metabolism (00260),
pyruvate metabolism (00620)
DB01169, DB00262, DB00143,
DB00157
Arsenic trioxide, Carmustine, NADH Approved, investigational;
approved; approved,
nutraceutical (2)
4 Q601P3 Purine metabolism (00230), pyrimidine
metabolism (00240)
DB00242, DB00631, DB01073,
DB00441, DB01005
Cladribine, Clofarabine, Fludarabine,
Gemcitabine, Hydroxyurea
Approved, investigational (2);
approved (3)
5 Q601I9 Purine metabolism (00230), pyrimidine
metabolism (00240), RNA polymerase
(03020)
DB00615 Rifabutin Approved
6 Q5ZZS1 Purine metabolism (00230), pyrimidine
metabolism (00240), RNA polymerase
(03020)
DB00615, DB01045, DB01220 Rifabutin, Rifampin, Rifaximin Approved (2); approved,
investigational
7 Q601C1 Pyrimidine metabolism (00240),
selenocompound metabolism (00450)
DB00548 Azelaic acid Approved
8 Q600B3 Pyrimidine metabolism (00240) DB00548 Azelaic acid Approved
9 Q601P8 Valine, leucine and isoleucine degradation
(00280), inositol phosphate metabolism
(00562), propanoate metabolism (00640)
DB00157, DB00165, DB00534,
DB00139, DB00116, DB00755,
DB00162, DB01612, DB00822,
DB00536, DB00435, DB00727
NADH, Pyridoxine, Chlormerodrin,
Succinic acid, Tetrahydrofolic acid,
Vitamin A, Amyl nitrite, Disulﬁram,
Guanidine, Nitric oxide, Nitroglycerin
Approved, nutraceutical (5);
approved (5); approved,
investigational; approved,
nutraceutical, investigational
10 Q602C0 Aminoacyl-tRNA biosynthesis (00970) DB00142, DB00130 L-Glutamic Acid, L-Glutamine approved, nutraceutical;
approved, nutraceutical,
investigational
11 Q601Y5 Aminoacyl-tRNA biosynthesis (00970) DB00135 L-Tyrosine approved, nutraceutical
12 Q601S3 Aminoacyl-tRNA biosynthesis (00970) DB00133 L-Serine approved, nutraceutical
13 Q601G1 Aminoacyl-tRNA biosynthesis (00970) DB00142 L-Glutamic Acid approved, nutraceutical
14 Q5ZZL4 Aminoacyl-tRNA biosynthesis (00970) DB00161, DB00167, DB00410 L-Valine, L-Isoleucine, Mupirocin approved, nutraceutical (2);
approved, investigational
15 Q601W6 Ribosome (03010) DB00479, DB06696, DB00452,
DB00798, DB01172, DB00994,
DB00955, DB00919, DB01082,
DB00560, DB00684
Amikacin, Arbekacin, Framycetin,
Gentamicin, Kanamycin, Neomycin,
Netilmicin, Spectinomycin, Streptomycin,
Tigecycline, Tobramycin
Approved (10); approved,
investigational
16 Q601L5 Ribosome (03010) DB01256 Retapamulin approved
17 Q601L4 Ribosome (03010) DB01321 Josamycin approved
18 Q601L1 Ribosome (03010) DB00759, DB00560 Tetracycline, Tigecycline approved
19 Q601J1 Ribosome (03010) DB00560 Tigecycline approved
20 Q5ZZW4 Ribosome (03010) DB00453, DB00618, DB00254,
DB00256, DB01017, DB00595
Clomocycline, Demeclocycline,
Doxycycline, Lymecycline, Minocycline,
Oxytetracycline
Approved (4); approved,
investigational (2)
21 Q5ZZN6 Ribosome (03010) DB00453, DB00618, DB00254,
DB00256, DB01017, DB00596,
DB01301, DB00560
Clomocycline, Demeclocycline,
Doxycycline, Lymecycline, Minocycline,
Oxytetracycline, Rolitetracycline,
Tigecycline
Approved (6); approved,
investigational (2)
22 Q600N3 Homologous recombination (03440) DB00173 Adenine approved, nutraceutical
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bacterial growth in both experimental and infectious conditions [7].
In summary the computational comparative and subtractive genomic/
proteomic analysis of different metabolic pathways resulted in a step
wise reduction (Fig. 4) and identiﬁcation of several proteins of
M hyopneumoniae that can be targeted for effective drug design and
vaccine development. As many of the identiﬁed drug targets have been
reported to play a role in the critical metabolic pathways that regulate
bacterial growth, energy metabolism, protein biosynthesis and essential
nutrient uptake, a systematic approach todevelopdrugs against these tar-
gets would help to combat the chronic swine pneumonia caused by this
pathogen. As thedrugsdeveloped thisway are also expected tobe speciﬁc
to the pathogen the development of antibacterial drug resistance and tox-
icity for the host could be minimized. Experimental investigation on dual
functions of a single identiﬁed target protein and in combination as drug
and vaccine candidate at the same time is underway.4. Materials and methods
4.1. Genomic proteome databases and alignment tools
The Refseq genomic nucleotide sequences and genomic Refseq
protein sequence of four strains of M. hyopneumoniae (Refseq:
NC_006360.1, NC_007332.1, NC_007295.1 and NC_017509.1) and
standalone release of NCBI BLASTP+ version 2.2.27(ftp://ftp.ncbi.
nlm.nih.gov/blast/executables/blast+/LATEST/) were downloaded
on a local machine and BLASTP was installed. Additionally, se-
quences of experimentally veriﬁed essential genes and proteins
from 22 Gram-positive and Gram-negative bacteria (Table S1) from
the latest update (version 7; November 11, 2012) of the Database
of Essential Genes (DEG) [45,46] containing 6711 drug entries,
including 1441 FDA-approved small molecule drugs, 134 FDA-
approved biotech (protein/peptide) drugs, 84 nutraceuticals, and
Fig. 3. Distribution of essential proteins in metabolic pathways. Percentage distribution of essential non homologous proteins of M. hyopneumoniae into their associated pathways
before (A) and after (B) the essential non homologous proteins/genes were analyzed by homology search of DrugBank database. (* 24 metabolic pathways whose essential non
homologous percentage distribution ranges from 0.8 to 4%).
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tein (i.e. drug target/enzyme/transporter/carrier) sequences linked
to these drug entries from the DrugBank (http://www.drugbank.
ca/) were downloaded and saved locally [26]. For genome wide
analysis of putative target proteins of the pathogen, the locally
saved databases and the search engine were used as presented in
the systemic work ﬂow (Fig. 1) and as described below deliberated
for the reductive analysis of comparative genomics for the identiﬁcation
of putative therapeutic and vaccine targets against M. hyopneumoniae.
Besides the locally saved databases, other online databases and NCBI
BLAST search were used as required.
4.2. Host and pathogen metabolic pathway analysis using KEGG
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database
(http://www.genome.jp/kegg) through its link to NCBI databases
was used for genome wide pathways analysis of the four strains of
whole genome sequenced M. hyopneumoniae and retrieval of theirFig. 4. Summary of target protein identiﬁcation. Number of proteins in stepwise
subtractive analysis of whole proteome of M. hyopneumoniae in drug target and vaccine
candidate protein identiﬁcation.information [24,25]. A list ofmetabolic pathways and the respective infor-
mation of the host (swine), human and the pathogenM. hyopneumoniae
were retrieved and saved locally. A manual comparison was conducted
and pathways that did not appear in the host and human but were
present in the pathogen, according to the KEGG database annotations
were selected as unique pathways to M. hyopneumoniae, whereas the
remaining pathways were listed as common pathways. Proteins from
common and unique pathways were identiﬁed and the respective
amino acid sequences were selected from the NCBI downloaded patho-
gen genome database.
4.3. Selection of non homologous and non homologous essential
pathogen proteins
A two step comparison of the pathogen proteome from both
unique and common pathways, ﬁrst with host proteome for identiﬁ-
cation of non homologous proteome of the pathogen and then a sec-
ond step similarity search of the identiﬁed non homologous proteins
of the pathogen against the protein sequences of the essential genes/
proteins from the database of essential gens (DEG) for the identiﬁca-
tion of the essential non homologous proteins of the pathogen were
performed with BLASTP analysis. The comparative searches against
the host were restricted to the host proteins through an option avail-
able under BLASTP parameters. Hits were ﬁltered on the basis of ex-
pectation value (e value) inclusion threshold being set to 0.005, and
a minimum bit score of 100. Proteins that didn't have hits below the
e value inclusion threshold were picked out as non homologous
proteins of the pathogen. These proteins were further screened on
the basis of essentiality using DEG at cut off e value of 10−10 and a
minimum bit score of 100 using DEG microbial BLASTP (Zhang et
al., 2004).
4.4. Prioritization of essential non homologous proteins of the pathogen
for drug target
The molecular and structural criteria proposed to aid in prioritizing
suitable therapeutic targets in pathogenic microorganisms [1] such as
calculation of molecular weight (MW) using computational tools and
drug target-associated literature available in the Swiss-Prot database
[5], prediction of biological signiﬁcance and subcellular localization of
therapeutic targets using CELLO v.2.5 (multi-class support vector
machine classiﬁcation system) [44] and TMHMM v2.0 (Transmembrane
predictions; http://www.cbs.dtu.dk/services/TMHMM/) [27] were
55D. Damte et al. / Genomics 102 (2013) 47–56performed on the identiﬁed target proteins. Additionally, experi-
mentally and computationally solved 3D structures were detected
by searching the Protein Data Bank (PDB) (http://www.rcsb.org/pdb)
[3,4] and ModBase (http://salilab.org/modbase) [36] databases, respec-
tively. The MAPPP (MHC-I Antigenic Peptide Processing Prediction/
http://www.mpiib-berlin.mpg.de/MAPPP/expertquery.html) with the
SYFPEITHY matrix which combines existing prediction tools for
proteasomal processing and MHC class I anchoring were used for pep-
tide prediction [20].
4.5. Druggability of essential non homologous proteins of the pathogen
The druggability potential, the likelihood of being able to develop
a drug-like compound to modulate the target, of each identiﬁed drug
targetwas evaluated by aligning the pathogen targetwith theDrugBank
contents of all and FDA-approved drugs, small molecule drugs, biotech
(protein/peptide) drugs and nutraceuticals. A BLASTP with default
parameters was performed to align the potential drug targets from the
pathogen against the list of protein targets of compounds of the men-
tioned data baseswithinDrugBankwith a selection criterion forﬁltering
as described previously for identiﬁcation of drug targets in bacterial
genomes [22].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.04.011.
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